Table 7b: PGADS: Treatment Effects of Etoricoxib 30 mg Relative to Comparators

95% CrI Probability that Etoricoxib 30 mg Shows Clinical Improvement Relative to Comparator (≥ 10 mm VAS)
Comparator (mg) Difference in CFB* Low High
nsNSAIDs
naproxen 1000 -1.3 -6.8 4.1 0.00
ibuprofen 2400 -5.2 -10.0 -0.4 0.03
diclofenac 150 2.0 -3.2 7.1 0.00
COX-2 selective NSAIDs
celecoxib 200 0.5 -3.2 4.2 0.00
lumiracoxib 100 -2.3 -10.2 6.1 0.03
lumiracoxib 200 -2.5 -10.4 5.9 0.03
lumiracoxib 400 -0.3 -8.5 7.6 0.01

* Negative effect sizes indicate improvement.